ALBO - Albireo Pharma achieves positive phase 3 top-line results of Bylvay in Alagille syndrome

• Top-line data for a phase 3 trial of Albireo Pharma's ( NASDAQ: ALBO ) Bylvay (odevixibat) in Alagille syndrome showed the candidate met its primary endpoint of significant improvement in pruritus .
• Shares are up 17% in premarket trading.
• It also met a secondary endpoint, reduction in serum bile acids.
• Data showed that in the treatment arm, the reduction in pruritus was 1.69 points based on the PRUCISION Observer-Reported Outcome scratching score (0-4 point scale), from baseline to month 6 compared to a 0.8 point improvement in the placebo group.
• Alagille syndrome is a rare disease characterized by bile buildup in the liver impacting ~25K people worldwide.
• Albireo ( ALBO ) is patients is also examining Bylvay in a phase 3 trial for biliary atresia. Top-line data is anticipated in 2024.
• In the US, Bylvay is already approved for pruritus in patients 3 months  and older in all types of progressive familial intrahepatic cholestasis.
• Check out why Seeking Alpha contributor BioSci Capital Partners is bullish on Albireo ( ALBO ).

For further details see: